Research Nester has released a report titled Pneumococcal Vaccine Market: Global Demand Analysis & Opportunity Outlook 2027” delivers detailed overview of the global pneumococcal vaccine market in terms of market segmentation by vaccine type, sector type, product type, distribution channel type and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
The global pneumococcal vaccine market is segmented into vaccine type, sector type, product type and distribution channel type.The global pneumococcal vaccine market is anticipated to record a CAGR of around 6.22% over the forecast period i.e. 2019-2027, owing to increase in pneumococcal disease incidences globally and growing awareness among the people. The increasing government support to eradicate the disease coupled with introduction of new and better vaccines with time is expected to increase the product demand during the forecast period. The conjugate vaccine segment is anticipated to hold the leading market share on the back of use of these vaccines for infants up to 5 years and adults above 50 years. Additionally, the private sector is anticipated to hold leading market share, owing to high cost of vaccines in private hospitals and healthcare centers as compared to public sector. The prevnar13 and non-government distribution channels are anticipated to record significant growth over the forecast period.
The market in North America is anticipated to witness significant market growth, owing to the presence of key market players and high awareness about the vaccine in the region. Owing to high adoption of vaccines and proper implementation of regular immunization program, Europe is anticipated to hold the leading market share. The market in Asia-Pacific is expected to record a CAGR of around 7% over the forecast period, owing to increased private sector investment in healthcare sector and increased awareness in the region. The market in Middle East and Africa region is anticipated to record an increase in the market share on account of increasing awareness and rise in government and non-governmental initiatives.
The growing awareness about the disease and vaccination, coupled with government initiatives and investments in the healthcare sector is expected to increase the market growth over the forecast period. Additionally, the rise in financial funding and programs, coupled with ongoing expansion projects are anticipated to boost the growth of the market. However, high production cost with long production cycles, coupled with side effects of the vaccination are expected to operate as key restraints to the growth of global pneumococcal vaccine market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global pneumococcal vaccine market which includes company profiling of Glaxosmithkline PLC, Merck & Co., Pfizer Inc, Panacea Biotec Limited, Pnuvax Incorporated, Serum Institute of India Pvt. Ltd, Shenzhen Kangtai Biological Products Co., Ltd., Walvax Biotechnology and Lanzhou Institute of Biological Products Co., Ltd
The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global pneumococcal vaccine market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.